Efficacy and Side Effects of Deferiprone (L1) in Thalassemia Patients Not Compliant with Desferrioxamine

Publisher： Karger

E-ISSN： 1421-9662|101|4|173-177

ISSN： 0001-5792

Source： Acta Haematologica, Vol.101, Iss.4, 1999-07, pp. : 173-177

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immune Status of Thalassemic Patients Receiving Deferiprone or Combined Deferiprone and Desferrioxamine Chelation Treatment

By  

Acta Haematologica, Vol. 110, Iss. 4, 2003-12 ,pp. : 224-226

Karger

Access to resources Recommend Favorite

Combined Chelation Therapy with Daily Oral Deferiprone and Twice-Weekly Subcutaneous Infusion of Desferrioxamine in Children with β-Thalassemia: 3-Year Experience

By  

Acta Haematologica, Vol. 133, Iss. 2, 2014-11 ,pp. : 226-236

Karger

Access to resources Recommend Favorite

Deferiprone Chelation Therapy for Thalassemia Major

By  

Acta Haematologica, Vol. 122, Iss. 2-3, 2009-11 ,pp. : 155-164

Karger

Access to resources Recommend Favorite

Evaluation of the Incidence of Sensorineural Hearing Loss in Beta-Thalassemia major Patients under Regular Chelation Therapy with Desferrioxamine

By  

Acta Haematologica, Vol. 108, Iss. 2, 2002-08 ,pp. : 79-83

Karger

Access to resources Recommend Favorite

The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β‐thalassemia major: A prospective, single center, open‐label study

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1592-1596

John Wiley & Sons Inc

Access to resources Recommend Favorite